The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial

Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) receptor function in schizophrenia, but they have yielded mixed results. Luvadaxistat, a D-amino acid oxidase (DAAO) inhibitor that increases the glutamate co-agonist D-serine levels, is being developed for the treatment of cogni...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Donnell, Patricio, Dong, Cheng, Murthy, Venkatesha, Asgharnejad, Mahnaz, Du, Xiaoming, Summerfelt, Ann, Lu, Hong, Xu, Lin, Wendland, Jens R., Dunayevich, Eduardo, Buhl, Derek L., Litman, Robert, Hetrick, William P., Hong, L. Elliot, Rosen, Laura B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018616/
https://www.ncbi.nlm.nih.gov/pubmed/36928351
http://dx.doi.org/10.1038/s41386-023-01560-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018616/
https://www.ncbi.nlm.nih.gov/pubmed/36928351
http://dx.doi.org/10.1038/s41386-023-01560-0

Ejemplares similares